- Home
- FDS vs GMAB Comparison
FDS vs GMAB Comparison
Compare FDS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDS
- GMAB
- Stock Information
- Founded
- FDS 1978
- GMAB 1999
- Country
- FDS United States
- GMAB Denmark
- Employees
- FDS N/A
- GMAB N/A
- Industry
- FDS Computer Software: Programming Data Processing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FDS Technology
- GMAB Health Care
- Exchange
- FDS Nasdaq
- GMAB Nasdaq
- Market Cap
- FDS 17.6B
- GMAB 17.4B
- IPO Year
- FDS 1996
- GMAB N/A
- Fundamental
- Price
- FDS $262.71
- GMAB $28.66
- Analyst Decision
- FDS Hold
- GMAB Strong Buy
- Analyst Count
- FDS 10
- GMAB 7
- Target Price
- FDS $356.78
- GMAB $41.50
- AVG Volume (30 Days)
- FDS 848.6K
- GMAB 2.6M
- Earning Date
- FDS 12-18-2025
- GMAB 11-06-2025
- Dividend Yield
- FDS 1.68%
- GMAB N/A
- EPS Growth
- FDS 11.79
- GMAB 132.41
- EPS
- FDS 15.55
- GMAB 25.10
- Revenue
- FDS $2,321,748,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- FDS $6.17
- GMAB $24.92
- Revenue Next Year
- FDS $5.44
- GMAB $15.97
- P/E Ratio
- FDS $16.89
- GMAB $11.14
- Revenue Growth
- FDS 5.39
- GMAB 29.57
- 52 Week Low
- FDS $250.50
- GMAB $17.24
- 52 Week High
- FDS $499.87
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- FDS 35.13
- GMAB 40.06
- Support Level
- FDS $250.50
- GMAB $28.08
- Resistance Level
- FDS $293.85
- GMAB $29.35
- Average True Range (ATR)
- FDS 8.11
- GMAB 0.65
- MACD
- FDS -0.62
- GMAB -0.27
- Stochastic Oscillator
- FDS 26.36
- GMAB 25.93
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.